Vascular Biology in Clinical Practice © Vol. 4, No. 2
• Beta-blocker therapy in heart failure: The new vascular biology imperative to blunt progression
This monograph, Beta-blocker therapy in heart failure: The new vascular biology imperative to blunt progression, is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine. Coeditors are Carl J. Pepine, MD and William Parmley, MD.
Beta-blockers have been evaluated in more than 10,000 patients with stable heart failure in long-term placebo-controlled clinical trials. This monograph highlights several new studies that have examined the safety and efficacy of beta-blockers in new subgroups of patients. The results should accelerate the use of beta-blockade in a wider range of patients with heart failure to lower their risk of morbidity and mortality. The monograph also discusses the scientific rationale for beta-blockade in heart failure.